Parsaclisib Incyte Biosciences Distribution B.V.: Withdrawal of the marketing authorisation application



Incyte Biosciences Distribution B.V. withdrew the application for a marketing authorisation of its medicine, Parsaclisib Incyte Biosciences Distribution B.V., for the treatment of marginal zone lymphoma, a cancer of the white blood cells.

The company withdrew the application on 27 June 2022.

  • List item

    Questions and answers on the withdrawal of application for the marketing authorisation of Parsaclisib Incyte Biosciences Distribution B.V. (parsaclisib) (PDF/144.14 KB)

    First published: 22/07/2022
    Last updated: 08/11/2022

  • Key facts

    Parsaclisib Incyte Biosciences Distribution B.V.
    Product number
    International non-proprietary name (INN) or common name
    • parsaclisib
    Active substance
    • Parsaclisib hydrochloride
    Date of withdrawal
    Company making the application
    Incyte Biosciences Distribution B.V.
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating